Results 61 to 70 of about 17,271 (194)
ABSTRACT Background Androgen receptor pathway inhibitors (ARPIs) such as abiraterone and enzalutamide are common therapies in the management of metastatic castration‐resistant prostate cancer (mCRPC). However, the comparative effectiveness of these oral ARPIs in frail and comorbid patient populations remains uncertain.
Meghana Yellanki +6 more
wiley +1 more source
Human Prostate Cell Lines: Derivation, Molecular Characteristics and Appropriate Use
ABSTRACT Background Research on prostate cancer and benign prostatic hyperplasia depends on a small number of immortalized human cell lines established between 1977 and 2001, most of them from advanced metastatic disease. The cell lines differ from one another in androgen receptor status, prostate‐specific antigen secretion, p53 status, karyotype and ...
Hamza Abohamra, Keenau Mark Pearce
wiley +1 more source
Comparative effectiveness of apalutamide‐, abiraterone‐, and enzalutamide‐based doublets in mHSPC
Background and Objective Treatment of metastatic hormone‐sensitive prostate cancer (mHSPC) has evolved from androgen‐deprivation therapy (ADT) alone to combination therapy with androgen receptor pathway inhibitors. Although apalutamide (APA), abiraterone (ABI), and enzalutamide (ENZA) improve outcomes when added to ADT, direct comparative trials ...
Anikó Katalin Valikovics +9 more
wiley +1 more source
Strategies for managing ACTH dependent mineralocorticoid excess induced by abiraterone.
BACKGROUND: Abiraterone strongly inhibits androgen synthesis but may lead to an increase in mineralocorticoid hormones that may impair its long term tolerability in patients with prostate cancer.
Pia A +16 more
core +2 more sources
Background The value of continuation of luteinizing hormone-releasing hormone (LHRH) therapy in castration-resistant prostate cancer (CRPC) remains controversial and clear evidence is lacking.
Carsten-Henning Ohlmann +6 more
doaj +1 more source
ADAM19 is associated with EMT‐related malignant phenotypes and NOTCH/NF‐κB pathway activity in RCC and may serve as a prognostic biomarker in CTCs. ABSTRACT Detection of circulating tumor cells (CTCs), particularly characterization of their epithelial‐mesenchymal transition (EMT) phenotypes, may improve prognostic accuracy for malignancies ...
Minxin He +8 more
wiley +1 more source
Interleukin‐12: Central Roles in Immune Regulation and Disease Therapy
IL‐12 levels are tightly regulated to balance effective protective immunity against infections and cancer with the risk of excessive inflammation and autoimmune disease. Both insufficient and excessive IL‐12 activity can therefore be detrimental, highlighting the importance of precisely controlling its production and signaling. ABSTRACT Interleukin‐12 (
Anthi Psoma, Geert van den Bogaart
wiley +1 more source
ABSTRACT Introduction We report a case of de novo prostatic adenosquamous carcinoma with a minute squamous component in the initial biopsy and early liver metastasis despite a marked prostate‐specific antigen response. Case Presentation A 72‐year‐old man was diagnosed with locally advanced prostate cancer with nodal and multiple bone metastases ...
Yohei Tsubouchi +9 more
wiley +1 more source
Antiandrogen‐resistant prostate cancer cells acquire ferroptosis resistance through AMPKα activation and upregulation of ferroptosis suppressor pathways. This adaptive state creates a therapeutic vulnerability, as GPX4 inhibition, particularly in combination with AMPKα inhibition, effectively suppresses the growth of resistant cells.
Masaki Shiota +8 more
wiley +1 more source
Intro: Abiraterone, an androgen blend inhibitor, was effectively utilized in cure of mutilation safe prostate malignant growth for 3 yr. Enzalutamide is the second-age nonsteroidal antiandrogen that has as of late been endorsed for identical sign ...
Dr Sarmad Khalil, Dr Saira Sarfraz, Dr Muhammad Younas
core +1 more source

